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ABSTRACT 
 
Wang, Jinju.  M.S., Department of Pharmacology and Toxicology, Wright State 
University, 2011. 
Differentiation of Megakaryocytes/Platelets and Neurons from Human 
Endometrial Stromal Progenitor Cells.1  
 
1 human endometrium is a high dynamic tissue that contains stem/progenitor 
cells. These endometrial stromal progenitor cells (hESCs) have been 
differentiated into a number of mesodermal lineages. There is limited information 
on differentiating hESCs into neurons, and no information on differentiating 
hESCs into megakaryocytes (MKs) and platelets (PLTs). The aim of this work 
was to investigate the possibility of differentiating hESCs into two distinct 
lineages: MKs, with subsequent PLT formation, and neurons. 
We isolated hESCs from human endometrial tissue and cultured the cells for 4-6 
passages. Before each differentiation experiment, the purity of hESCs was 
confirmed by flow cytometry analysis which revealed that the cells were highly 
positive (>95%) for CD90 and CD29 (stromal cell markers), and were negative 
(<1.3%) for CD45 and CD34 (hematopoietic cell markers). 
For MKs differentiation, hESCs (1.8×105 cells/well) were cultured in serum-free 
medium either with (differentiation) or without (control) thrombopoietin (TPO, 50 
ng/ml) for 18 days. MKs differentiation was analyzed by flow cytometry and 
confocal microscopy. PLTs were collected from culture medium supernatant from 
day10-18, and were defined by flow cytometry and functional study. Our results 
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show: 1) MKs were successfully generated as evidenced by expression of MK 
membrane markers (CD41a: 39 ± 3.0% and 1 ± 0.09%; CD42b: 28 ± 2.0% and 
1.2 ± 0.06%, differentiation vs. control, n=3). 2) Immunocytochemistry analysis 
showed the differentiation rate of CD41a (38 ± 3.0%) and CD42b (27 ± 2.5%). 3) 
Generated PLTs were positively labeled with CD41a (90 ± 2%). 4) Functional 
study of generated PLTs revealed that thrombin (5 U/ml) stimulation up-regulated 
CD62P expression (26.0 ± 4% and 2.5 ± 1%, thrombin vs. control, n=3), and 
fibrinogen binding (32 ± 3.0% and 1 ± 0.4%, thrombin vs. control, n=3). 5) 
Electronic microscopic examination showed that generated PLTs had similar 
ultrastructure (storage granules) as normal human peripheral blood PLTs. 
For neuron differentiation, hESCs (1.6×105 cells/well) were cultured in medium 
either with (differentiation) or without (control) cytokines (FGF, EGF, NGF and 
BDNF) for 14 days. Differentiated neurons were analyzed by confocal 
microscopy and western blot analysis. Our results show: 1) neurons were 
successfully generated as evidenced by phenotypic expression of neuron 
specific markers nestin (40 ± 4%), β-tublin III (37 ± 3%), NeuN (15 ± 2%), TH (14 
± 1%), and astrocyte marker GFAP (10 ± 3%). 2) Western blot analysis showed 
that the expression of transcription genes (Oct4: 0.11 ± 0.01and 0.32 ± 0.01; 
Sox2: 0.25 ± 0.02 and 0.52 ± 0.03, differentiated vs. control, n=4) was down-
regulated in differentiated neurons.   
Taken together, these data indicate that it’s feasible to generate MKs, functional 
PLTs and neurons from hESCs. The hESCs could be a potential source for cell-
based therapy in regenerative medicine. 
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I. INTRODUCTION AND PURPOSE 
Structure of Human Endometrium 
The endometrium, or uterine mucosa, presents the most inner layer of the uterine 
wall. It is comprised of an epithelial lining and underlying stroma. The surface 
(simple columnar) epithelial cells that line the uterine cavity are situated on a 
basement membrane. Deep to the surface epithelium are glands that extend the 
full thickness of the mucosa. The glands are separated from each other by a 
highly cellular connective tissue. Deep to the stroma is the muscular myometrium, 
which forms the middle and outer uterine wall.  
The endometrium is structurally and functionally divided into two major zones, 
the upper functionalis layer and the lower basalis layer (Gargett, 2007) (Fig1). 
The functionalis layer is shed at menstruation and is subsequently regenerated 
each month from putative progenitor cells located in the remaining basalis zone 
(Padykula, 1991). 
Endometrium of reproductive-age females is highly dynamic. It has a remarkable 
capacity for self-renewal, undergoing more than 400 complete cycles of 
regeneration, differentiation and shedding during the reproductive years (Gargett 
et al, 2008). After the endometrium is shed as part of the physiologic, normal 28-
day menstrual cycle, it regenerates to a thickness of 4-7 mm within 4-10 days 
(McLennan & Rydell, 1965). The regenerative capacity of human endometrium is 
believed to be at least equivalent to many highly regenerative organs, such as 
epidermis, intestinal epithelium and bone marrow, where adult stem cells 
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replenish lost cells to maintain tissue homeostasis (Fuchs & Segre, 2000;Li & Xie, 
2005). 
Fig 1. Diagram demonstrating the histologic structure of human endometrium.   
The endometrium is divided into two major zones: upper functionalis and 
lower basalis layers (Adapted from Gargett et al., 2007).
 
 
Presence of Stromal Progenitor Cells in Human Endometrium 
The hypothesis that the regenerative ability of endometrium is mediated by adult 
stem cells or a progenitor cell population was proposed more than two decades 
ago. It was based on the evidence from histological studies of human and 
primate endometrium (Padykula et al, 1984; Padykula, 1991; Prianishnikov, 
1978). However, initial evidence for stem/progenitor cells activity in human 
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endometrium was not reported until 2004. In that year, Chan and coworkers 
isolated stromal and epithelial stem cells exhibiting a high proliferative potential 
(Chan et al, 2004). Later, the same group identified the clonogenic epithelial and 
stromal cells in active, cycling and inactive endometrium (Schwab et al, 2005). 
Further evidence included that endometrial stromal cells are able to differentiate 
into multiple cell lineages. Wolff et al found that only the endometrial stromal cells 
can be differentiated into chondrocytes in a defined medium, as compared with 
other monolayer cells generated from myometrial, fibroid, fallopiantube, and 
uterosacral ligament tissue (Wolff et al, 2007). Most recently, The Dimitrov group 
reported that human endometrial stromal progenitor cells (hESCs) can be 
cultured for more than 15 passages and showed high clonogenic efficiency (15%) 
(Dimitrov et al, 2008). Gargett et al described that single endometrial stromal cell 
can form cellular colonies that can be further serially cloned. Further, it was 
shown that cloned stromal cells can be differentiated into mesodermal lineages 
including adipogenic, osteogenic, myogenic and chondrogenic cells in the 
presence of corresponding inducing factors (Gargett et al, 2009). Taken together, 
these findings strongly indicate that multipotent stromal stem/progenitor cells 
exist in human endometrium. The putative location of these cells is near blood 
vessels in the basalis layer of endometrium (Gargett, 2007;Schwab et al, 2005) 
(Fig 2). 	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Fig 2. Diagram illustrating putative location of endometrial stem/progenitor  
cells. Dotted line designates separation between the functionalis and basal 
layers. Progenitor cells are located in the basal layer, near blood vessels 
(Adapted from Gargett et al., 2007).
	  
 
Menorrhagia: a Common Bleeding Disorder in Reproductive-age Females 
Menorrhagia is defined as excessively heavy uterine bleeding during normal 
menstrual cycle intervals and corresponds in adult females to more than 80mL of 
blood loss per menstrual period. It is common among women of reproductive 
ages. Women with menorrhagia may experience diminished quality of life 
parameters, psychosocial issues in addition to developing anemia, diminished 
reproductive capacity and untoward pregnancy complications. It also places 
women with this disorder at an increased risk of having unnecessary 
hysterectomies and other gynecological procedures (Gould, 1995;Hickey & 
Fraser, 1995). Indeed, one-third women in the United States have 
hysterectomies before the age of 60 years and menorrhagia is the main 
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presenting problem in at least one-half of these women. Approximately one-half 
of women who have a hysterectomy for menorrhagia are found to have an 
anatomically normal uterus indicating that other causes are responsible for the 
heavy uterine bleeding (Duckitt & Collins, 2008). 
Menorrhagia is a common symptom of von Willebrand disease (vWD) in adult 
presenting with menorrhagia (Lusher, 1996). Recent studies have demonstrated 
that menorrhagia also is prevalent in adolescent girls with inherited bleeding 
disorders, particularly in those with PLT function disorders (PFDs) (Chi et al, 
2010;El-Hemaidi et al, 2007;Hossain et al, 2010). PFDs are inherited 
heterogeneous disorders. The most common PFD subtype, dense granule 
storage pool deficiency, is a heterogeneous disorder and is frequently found 
among patients with mild to moderate bleeding diatheses that do not have vWD. 
Because PLT dense granules contain proaggregation factors for the formation of 
a haemostatic plug, the overall consequence of poor PLT plug formation result in 
clinical bleeding disorders, of which menorrhagia is a common problem. Patients 
with the PFD subtype dense granule storage pool deficiency that experience  
menorrhagia refractory to medical therapy are in some cases treated with PLT 
transfusions. One objective of the thesis is to use ex vivo methods to generate 
MKs and PLTs from human endometrial stem/progenitor cells. The overall aim is 
to then evaluate them for use as a novel therapeutic modality in the treatment of 
menorrhagia in both adult and adolescent females, from all ethnic-ancestral 
backgrounds, with menorrhagia and documented platelet storage pool (dense 
granule) defects. If PLTs with normal dense granules can be generated from 
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patients in an in vitro culture system, it will represent an important first step in 
using the patients’ own stem cells as a source of PLTs for autotransplantation or 
allotransplantation to treat PLT disorders. 
 
MKs and PLTs 
MKs are myeloid cells (constituting less than 1% of these cells) that reside 
primarily in the bone marrow (BM), and undergo a series of dynamic changes to 
become mature MKs (Nurden et al, 1997). Importantly, MKs are PLT precursor 
cells. Mature MKs are characterized morphologically by their large cell size, 
abundant cytoplasm, the presence of numerous intracellular granules and a 
distinctive demarcation membrane system (DMS). The DMS was originally 
thought to divide the MK cytoplasm into small fields where individual PLT would 
assemble to subsequently be released. PLTs are terminally differentiated cells 
that represent non-nucleated fragments of the MKs. PLTs have multifactorial 
roles. They are known to play a key role in haemostatic plug formation (Varga-
Szabo et al, 2008). They also participate in arterial thrombosis (Davi & Patrono, 
2007), the innate immune response and metastatic tumor cell biology 
(Kaushansky, 2009;van der Meer & Pietersz, 2005). PLTs circulate in the blood 
for a short life span of 7-10 days and need to be replaced in order to maintain 
normal levels in the blood (Hartwig & Italiano, Jr., 2003). The circulating 
concentration of PLTs is around 1.5 - 4.5 x 1011 per liter of blood in a healthy 
individual. The circulating PLT level is regulated by both PLT production and 
destruction. Megakaryocytopoiesis and thrombopoiesis are two essential 
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processes involved in PLT production (Kuter et al, 2001). Megakaryocytopoiesis 
starts with hematopoietic stem cells (HSCs) that undergo lineage commitment, 
proliferation and differentiation, all of which are regulated by various cytokines 
and growth factors. Thrombopoiesis is involved in the process of releasing 
functional PLTs into the circulation. Abnormalities in these processes can result 
in clinical bleeding disorders. For example, menorrhagia due to PLT disorders 
can be caused by either PLT deficiency (thrombocytopenia) or PLT dysfunction.  
PLT transfusion is widely used for treatment of various PLT-related diseases, 
such as thrombocytopenia and in cases of menorrhagia that are refactory to 
medical therapy (Blumberg et al, 2008;Kanbur et al, 2003;Nevo et al, 
2007;Stephan et al, 1999). In the United States, the total number of PLT 
transfusions is over 10 million units per year and is increasing annually. This 
steady increase in demand challenges the US blood transfusion community. 
Moreover, the short storage life of PLT concentrates, the risk of pathogenic 
contamination, and the variability of quality and quantity of the donor-derived 
PLTs compromise the supply of PLTs from traditional donor-dependent method 
of harvesting PLTs (Matsunaga et al, 2006;Stevens et al, 2006). Thus, the 
search for developing an alternative approach to produce large numbers of PLTs 
is intensely appealing. To this end, producing PLTs from stem cells holds great 
promise as an alternative approach. 
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Generation of MKs and PLTs from Stem Cells in vitro 
Thrombopoietin (TPO), also known as c-Mpl ligand, is a growth factor and a key 
physiological regulatory factor that induces MK proliferation and maturation 
(Alexander et al, 1996;Gurney et al, 1994;Kaushansky et al, 1994;Kaushansky, 
1995). The in vitro use of TPO renders possible the generation of highly enriched 
MKs with normal structural features and function. Production of PLTs in vitro also 
has been attempted with the goal of using them for transfusions in patients with 
PLT disorders. Choi et al first demonstrated the feasibility of in vitro generation of 
functional PLTs by stimulating the release of PLTs from cultured MKs 
differentiated from human peripheral blood (Choi et al, 1995). After that, other 
investigators have successfully produced MKs and PLTs in vitro from HSCs and 
embryonic stem cells (Eto et al, 2002;Fujimoto et al, 2003;Gaur et al, 
2006;Matsunaga et al, 2006;Takayama et al, 2008), as well as from progenitors 
of subcutaneous adipose tissue (Matsubara et al, 2009). The culture-derived 
PLTs exhibit similar features to PLTs from peripheral blood with respect to 
morphology and function. Chen et al reported that transplantation of generated 
MKs can accelerate the recovery of MKs and PLTs and reduce 
thrombocytopenia in mice model (Chen et al, 2009). Furthermore, some clinical 
trials have shown transplantation of in vitro expanded MK progenitors into 
patients can boost PLTs recovery (Bertolini et al, 1997; Matsunaga et al, 2006; 
Paquette et al, 2000; Scheding et al, 2004). Groups led by Eto and Fujimoto 
developed approaches to generate a large amount of PLTs in vitro from murine 
embryonic stem cells (Eto et al, 2002; Fujimoto et al, 2003). Currently, no one 
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has reported on MK and PLT production from human endometrial-derived stem 
cells. 
 
Ischemic Stroke and Neuron Stem Cells 
Stroke can cause permanent neurological damage and are associated with many 
complications. It is one of the leading causes of death and disability worldwide 
and has an incidence of approximately 150-200  in 100,000 (Modan & Wagener, 
1992). There are 2 types of stroke: ischemic stroke and hemorrhagic stroke. 
Ischemic stroke is caused by occlusion of a blood vessel in the brain and 
constitutes the majority of stroke cases (85-90%) (Qureshi et al, 2001). 
Neurons are the core components of the nervous system. They are electrically 
excitable cells that process and transmit information to the central nervous 
systems via various electrical and chemical mechanisms. The nerve system has 
a limited capacity for self repair owing to the lack of mature neurons to undergo 
cell division. In most cases, mature neurons are regenerated by adult neural 
stem cells, which are found mainly in 2 regions in brain: subventricular zone 
(SVZ) of the lateral ventricles (LV) and subgranular zone (SGZ) in the dentate 
gyrus (DG) of the hippocampus (Lois & varez-Buylla, 1994). Even though adult 
neural stem cells have the capacity to generate new functional neurons, their 
regeneration is limited. This is in part due to newly generated neuron stem cells 
having to migrate long distances from the site of origin to the site of damage and 
subsequent repair. It has been reported that more than 80% of these immature 
neurons die before they reach the damaged region during the first week after 
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stroke, and only a small fraction of damaged neurons can be replaced (Arvidsson 
et al, 2002). Therefore, transplantation of in vitro generated neurons is a potential 
avenue for promoting cerebral repair after neuron damage.  
 
Generation of Neurons from Stem Cells In vitro 
Stem cells can differentiate into neural lineages that can in turn replace lost 
neurons. Preclinical experimental studies have included the application of human 
stem cells from various sources including BM stromal cells, embryonic stem cells, 
and adipose tissue progenitor cells (Deng et al, 2001; Lenka et al, 2002; Ning et 
al, 2006; Sanchez-Ramos et al, 2000; Woodbury et al, 2000). Transplanted 
embryonic neurons can survive and ameliorate neurological deficits in 
Parkinson’s and stroke models (Hicks et al, 2009; Kim et al, 2002; Rodriguez-
Gomez et al, 2007; Takagi et al, 2005), respectively. A recent study indicated 
that transplantation of dopaminergic neurons generated from endometrium could 
rescue dopamine concentrations in a Parkinson’s animal model (Wolff et al, 
2011). Furthermore, in a clinical trial, transplanted embryonic dopamine neurons 
have been shown to survive in vivo, leading to promising clinical success (Freed 
et al, 2001).  
 
Taken together, recent studies on generating MKs, PLTs and neurons from stem 
cells is of increasing interest, because of the promising role of MKs and PLTs in 
transfusion medicine and neurons in transplantation therapy. Stem cells sources 
include embryonic stem cells (Fujimoto et al, 2003; Gaur et al, 2006; Nishikii et al, 
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2008; Takayama et al, 2008) and HSCs from BM, peripheral blood (PB) and cord 
blood (CB) (Mattia et al, 2002; Proulx et al, 2003; Shim et al, 2004). However, 
there are several strengths and limitations of these sources. Human embryonic 
stem cells provide the feasibility of obtaining abundant of MKs, PLTs and 
neurons. However, ethical and political issues, potential for tumor formation and 
the sophisticated experiment technique inherent in their production are 
formidable obstacles. The limited proliferative ability of HSCs also has been 
pointed out as a limitation.  All of these issues hamper the widespread use of 
these sources. 
Recently endometrial tissue has been identified as a source of multipotent cells 
that are capable of differentiating into smooth muscle cells, adipocytes, 
chondrocytes, and osteoblasts (Gargett et al, 2009). hESCs can be relatively 
simply isolated and maintained in cell culture. Further, hESCs can be used as an 
autologous stem cell source, thereby obviating concerns regarding graft rejection 
in humans. Currently, there are no reports on generating MKs and PLTs from 
hESCs. And only one recent publication has even described the possibility of 
generating neurons from hESCs with combinational inducers (chemical 
compound and cytokines) (Wolff et al, 2011). In the present study, we explored 
whether hESCs could be differentiated into two distinct cell lines, MKs/PLTs and 
neurons, in in vitro culture systems.  
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II. HYPOTHESIS AND SPECIFIC AIMS 
 
Hypothesis:  
It is hypothesized that human endometrial stromal progenitor cells(hESCs) could 
be differentiated into MKs/PLTs or neurons in in vitro culture systems. 
Specific Aims: 
Aim-1: To set up a method to culture stromal progenitor cells from human 
endometrial tissue. 
Aim-2: To investigate the feasibility of differentiating hESCs into MKs in an in 
vitro culture system and to evaluate the function and morphology of PLTs 
released from the generated MKs. 
Aim-3: To explore the possibility of neuron differentiation from hESCs in an in 
vitro culture system. 
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III. EXPERIMENT DESIGN 
Aim-1: 
Endometrial tissues were collected from selected patients and transferred to the 
laboratory. The endometrium layer was then dissected, minced, and 
enzymatically digested into a single-cell suspension. The hESCs were cultured 
for 4-6 passages and identified by immunocytochemistry and flow cytometry 
analyses. 
Aim-2: 
Passages 4-6th of hESCs were cultured in serum-free medium with TPO (50 
ng/ml) (differentiation group) or without (control group) for to investigate their 
ability to differentiate into MKs and subsequently generate PLTs. Generated MKs 
were identified by flow cytometry and immunocytochemistry methods. Produced 
PLTs were collected from culture medium and analyzed by flow cytometry. The 
produced PLTs were characterized functionally by thrombin stimulation study 
coupled with flow cytometry analysis and electronic microscopic examination. 
 Aim-3: 
hESCs were cultured in medium with (differentiation group) or without (control 
group) cytokines (10 ng/ml EGF, 10 ng/ml FGF, 10 ng/ml NGF, 15 ng/ml BDNF) 
for investigating their ability for differentiating into neurons. Generated neurons 
were determined by immunocytochemistry and western blot analysis of the 
expressions of transcriptional genes (Oct4 and Sox2).  
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hESCs identification
P4-P6Collection of 
endometrial
tissue
1 hr IHC and flow cytometry
(CD90, cytokaretin,
CD29, CD34, CD45)
Isolation
and
culture
hESCs
IHC and flow cytometry
analysis of  MKs (CD41a, 
CD42b)
MK/PLT differentiation in medium 
containing thrombopoietin (TPO, 
50ng/ml) for 18 days
Functional study of PLTs
(thrombin stimulation induced
CD62p expression and 
Fibrinogen binding)
Transmission electron 
microscopy study of PLTs
1.8x105
cells/well 
Neuron differentiation in medium 
containing growth factors (EGF,
FGF,BDNF, NGF) for 14 days
WB analysis of 
transcription genes
expression (Oct4, Sox2)
IHC (nestin, β tubulin III, 
NeuN, TH, GFAP)
1.6×105 
cells/well 
 
Fig 3. The flow chart shows our experiment protocol. IHC: immunocytochemistry; 
WB: western  blotting. 
 
 
 
MATERIALS AND METHODS 
Materials 
Cytokines 
TPO and BDNF were purchased from BD Biosciences (San Jose, CA). FGF, 
EGF and NGF were purchased from Lonza (Walkersville, MD). 
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Antibodies 
PE-conjugated mouse anti-human CD90, PE-conjugated mouse anti-human 
CD29, FITC-conjugated mouse anti-human CD45, FITC-conjugated mouse anti-
human CD34, PE-conjugated mouse IgG1, FITC-conjugated mouse IgG1, FITC- 
conjugated mouse anti-CD62P, purified mouse anti-human CD41a, and purified 
mouse anti-human CD42b were purchased from eBioscience (San Diego, CA). 
FITC-conjugated mouse anti-human CD41a, FITC-conjugated mouse anti-human 
CD42b, FITC mouse IgG1 isotype control, and mouse anti-CD90 antibody were 
purchased from BD Biosciences (San Jose, CA). Mouse anti-Sox2 was 
purchased from R&D systems (Minneapolis, MN). Rabbit anti-Oct4 was 
purchased from Abcam Inc (Cambridge, MA). Cy3-conjugated donkey anti-
mouse, Cy3-conjugated donkey anti-rabbit, FITC-conjugated goat anti-rabbit,  
FITC-conjugated goat anti-mouse, and HRP-conjugated antibodies were 
purchased from Jackson lmmunoResearch Lab (West Grove, PA). Mouse anti-
cytokeratin antibody was purchased from Dako (Carpinteria, CA). Nestin, anti-
tubulin, NeuN, and TH were purchased from Millipore (Temecula, CA). GFAP 
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 
488-labeled human fibrinogen, Alexa Fluor 488-conjugated mouse IgG isotype 
control, and flow cytometry size calibration kit were purchased from Invitrogen 
(Carlsbad, CA). β-actin was purchased from Sigma (Fairfax, VA). 
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Reagents 
DMEM/F12, IMDM, iron saturated transferrin, L-glutamine, dNTP set, FBS, 
antibiotic-antimycotic solution, trypsin, and HEPEs were purchased from 
Invitrogen (Carlsbad, CA). NPBM was purchased from Lonza (Walkersville, MD). 
70 µM wire sieve was purchased from BD Biosciences (San Jose, CA). DNAse1, 
Human insulin, BSA, 2-β-mercaptoethanol, nucleotide kit, PI, RNAase, thrombin, 
glutaraldehyde,	  propylene oxide, and spurr resin 812 were purchased from 
Sigma (Fairfax, VA). Collagenase was purchased from Roche Applied Science 
(Indianapolis, IN). Uranyl acetate and lead citrate were purchased from Fisher 
Scientific (Pittsburgh, PA). Osmium tetroxide was purchased from Electron 
Microscopy Science (Hatfield, PA). 
	  
Methods 
Harvesting Human Endometrium Tissue Sample 
Premenopausal women (30-45 years old) who were undergoing hysterectomy for 
benign disease indications, leiomyoma, were selected. Informed consent was 
obtained by each patient and patient confidentiality was protected according to 
HIPPA guidelines. Ethics approval was obtained from the Institutional Review 
Boards and Research Committees at the Miami Valley Hospital and Wright State 
University Research Committee for this study. 
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Endometrium tissues were obtained for isolation and culture of hESCs. In brief, 
after the uterus was removed from the patient, a small tissue sample with full 
thickness endometrium attached to myometrium was dissected and collected 
immediately. The tissue sample was placed into 20 ml pre-chilled phosphate 
buffer saline (PBS) buffer containing 10% FBS and 2% antibiotic-antimycotic 
solution (final concentration: 200 µg/ml penicillin G sodium and 200 µg/ml 
streptomycin sulfate) and was processed within 30 - 60 min. 
Isolation and Culture of hESCs 
The endometrium tissue was mechanically and enzymatically digested into a 
single-cell suspension as previously reported with slight modifications (Chan et al, 
2004;Dimitrov et al, 2008). Briefly, the tissue sample was washed twice with 
washing buffer (PBS with 25 µM HEPEs and 1% antibiotic-antimycotic solution) 
to remove excess blood. Then the endometrium layer was dissected from the 
underlying myometrium, minced into 1-2 mm³ pieces with a sharp surgical 
scissor, digested in enzyme digestion buffer (PBS with 25 µM HEPEs, 1mg/ml 
collagenase, 0.1mg/ml DNAse1 and 1% antibiotic-antimycotic solution) in a 
humidified 5% CO2 / 95% air atmosphere at 37°C for 45 min with a brief shaking 
once every 5 min. Then cell suspension was filtered through a 70 µm wire sieve 
to remove mucus and undigested tissue. The filtrates were centrifuged at 400 × g 
for 10 min to collect cells. 0.9 ml ammonium chloride solution was added to lyse 
excess erythrocytes for 10 min on ice, followed by centrifugation at 400 × g for 10 
min, the cell pellets were resuspended with hESCs culture medium (DMEM/F12 
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supplemented with 10% FBS and 1% antibiotic-antimycotic solution). Cells were 
plated in 6-well tissue culture plates, allowed to adhere overnight in a humidified 
5% CO2/95% air atmosphere at 37°C and cultured as monolayer cells.  
For passaging, when cells reach 90% confluence, they were treated with 1.5 
ml/well 0.025% trypsin/0.01% EDTA at 37°C for 7 min, then an equal volume of 
complete DMEM/F12 with 10% FBS medium was added to deactivate the 
enzyme reaction. Cells were then pelleted. Supernatant was discarded. Pelleted 
cells were resuspended with hESCs culture medium, split in a 1:3 ratio and 
cultured until the 4th passage. The culture medium was replaced with fresh warm 
medium every 2-3 days.  
 
Identification Study of hESCs 
Cultured cells at the 4th passage were analyzed by indirect immunocytochemistry 
and flow cytometry as previous described (Dimitrov et al, 2008;Gargett et al, 
2009). 
In brief, for immunocytochemistry staining, a proportion of cells were seeded on 
coverslips and incubated overnight. After 2 washes with PBS, the cells were fixed 
with 2% paraformaldehyde (PFA) for 20 min, treated with blocking buffer (PBS 
with 3% BSA and 3% normal donkey serum) for 1hr at room temperature (RT). 
Subsequently the cells were incubated with primary monoclonal antibodies 
mouse anti-human CD90 (Thy-1) (1:25) or mouse anti-human cytokeratin (1:50) 
overnight at 4ºC. Following by 3 washes with PBS/0.1% BSA, the cells were 
incubated with secondary antibody, Cy3-conjugated donkey anti-mouse IgG 
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(1:250), for 1 hr at RT. Washed with PBS/0.1% BSA 3 times (3 min each), 
mounted with fluorescence mounting medium and imaged under a fluorescence 
microscope (Leica, Germany).  
For flow cytometry analysis, cells were trypsinized at 90% confluence as above 
described, centrifuged at 400 × g for 10 min. Cell pellets were resuspended and 
incubated with either PE-conjugated anti-human CD29 and FITC-conjugated 
anti-human CD45, or PE-conjugated anti-human CD90 and FITC-conjugated 
anti-human CD34 for 30 min at 4ºC in the dark, individually. Isotype matched 
(IgG) non-specific antibodies served as negative controls. Final volume per tube 
was brought to 100 µl for flow cytometric analysis using Accuri C6 flow cytometer 
and CFlow Plus Analysis software (Ann Arbor, MI). Cells were selected for 
analysis on the basis of their forward versus side scatter profile to exclude dead 
cells and debris. All antibody application concentrations followed manufacture 
instructions and guidelines. 
 
Differentiation of MKs and PLTs from hESCs 
In order to differentiate hESCs into the MK lineage, the 4th passage of hESCs 
were trypsinized with 0.025% trypsin/0.01% EDTA, centrifuged at 400 × g for 10 
min, counted using a hemacytometer, and seeded as1.8 x 105 cells/well on 6-well 
tissue culture plates or coverslipes with hESCs culture medium overnight. Then 
culture medium was removed and replaced with fresh induction IMDM medium 
supplemented with 50 ng/ml TPO, 0.5% BSA, 200 µg/ml iron saturated 
transferring, 10 µg/ml insulin, 2 mM L-glutamine, 4 µg/ml LDL cholesterol, 50 µM 
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2-â-mercaptoethanol, 20 µM each nucleotide, 20 µM dNTP and 1% antibiotic-
antimycotic solution. Cells were cultured for 18 days. One half of the culture 
medium was replaced in the first 10 days, then all of the culture medium was 
changed from day 10-18 to collect PLTs from the medium supernatant. Control 
cells were cultured in complete culture medium (IMDM with 10% FBS and 1% 
antibiotic-antimycotic solution) without TPO for 18 days. Cells on coverslips were 
used for MK immunocytochemistry studies.  
 
Characterization Study of MKs Differentiated from hESCs 
MKs generated from hESCs were determined by immunocytochemistry and flow 
cytometry analyses.  
For immunocytochemistry, cells on coverslips were fixed with 2% PFA for 20 min 
at RT, washed with PBS/0.1% BSA 3 times, permeabilized with goat serum 
blocking buffer (PBS/0.1% BSA and 0.3% triton-100) for 30 min at RT, then 
incubated with prediluted purified mouse anti-human CD41a (glycoprotein αIIb) 
and purified mouse anti-human CD42b (glycoprotein αIb) primary antibodies 
overnight at 4°C. The cells were washed 3 times (5 min each), then incubated 
with secondary antibody FITC-conjugated goat anti-mouse (1:100), individually, 
followed by another 3 washes, the cells were incubated with PI/PBS solution in 
the presence of RNAse (PI/RNAse final concentration: 20 µg/ml) for 15 min at RT 
in the dark, then mounted with fluorescence mounting solution and imaged under 
a confocal fluorescence microscope (Leica TCS SP2, Leica, Germany). To 
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assess the differentiation rate, we counted the number of cells staining positive 
with a given antibody in 5 individual fields. Control cells were stained 
concurrently. 
For flow cytometry, the cells were detached with 0.025% trypsin/0.01% EDTA, 
centrifuged at 800 × g for 10 min to pellet the MKs. MKs were then resuspended 
and fixed with 2% PFA for 20 min at RT, washed with PBS/0.1% BSA 3 times, 
centrifuged at 800 × g for 10 min, permeabilized with blocking buffer (PBS/0.1% 
BSA and 0.3% triton X-100) for 30 min at RT. This was followed by incubation 
with fluorescence conjugated antibodies, FITC-conjugated anti-CD41a, FITC-
conjugated anti-CD42b and FITC-conjugated mouse IgG1 isotype control, for 30 
min at 4°C in the dark, respectively. The cells were then washed with PBS/0.1% 
BSA, centrifuged and incubated with 100 µl PBS/0.1% BSA buffer with PI 
solution (20 ug/ml) containing RNAase (20 ug/ml) for 30 min at RT in the dark. 
Samples were analyzed by an Accuri C6 flow cytometer and CFlow Plus Analysis 
software. CD41a+cells were defined as MKs and were gated for MK ploidy 
analysis. All antibody application concentrations followed manufacture 
instructions and guidelines. Control cells were analyzed simultaneously.  
 
Characterization Study of PLTs Generated from hESCs 
PLTs released from generated MKs were defined by flow cytometry analysis. 
Briefly, culture medium was gently collected from day 10-18 with a 15 ml 
centrifuge tube and centrifuged at 150 × g for 20 min to eliminate any large cells. 
The supernatant was fixed with 2% PFA for 20 min at RT, centrifuged at 1700 × g 
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for 30 min to sediment a PLT pellet. When storing PLTs, the pellet was 
resuspended with PBS/1% FBS, and stored at 4°C for further analysis. Then 
fixed and stored PLT pellet were combined, resuspended and incubated with 
FITC-conjugated anti-CD41a antibody and FITC-conjugated mouse IgG1 isotype 
control for 30 min at 4°C in the dark, individually. The total volume per tube was 
brought to 100 µl with PBS/0.1% BSA. 2 µm and 4 µm flow cytometry calibration 
bead solution was added into each tube. All samples were analyzed using the 
Accuri C6 flow cytometer. The application concentrations of calibration beads 
and antibodies followed manufacture instructions and guidelines. 
 
Functional Study of Generated PLTs with Thrombin Stimulation 
The functional capabilities of generated PLTs were analyzed for both fibrinogen 
binding and surface antigen CD62P expression in the presence or absence of 
agonist thrombin.  
To prepare cell samples, PLTs were collected as described above. The PLT 
pellets were resuspended in a modified Tyrode-HEPEs buffer (138 mM NaCl, 
0.36 mM NaH2PO4, 2.9 mM KCl, 12 mM NaHCO3, 10 mM HEPEs, 5 mM glucose, 
1 mM MgCl2, and 1 mM CaCl2, pH 7.4). 
The ability of fibrinogen to bind surface receptors on activated PLTs is a 
prerequisite for PLT aggregation. To determine fibrinogen binding, PLTs were 
stimulated by thrombin (5U/ml) for 10 min at 37°C without stirring in the presence 
of Alexa Fluor 488-labeled human fibrinogen (100 µg/ml) or isotype control 
mouse IgG, respectively. A control group of PLTs underwent concurrent testing. 
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The control PLTs were stained with Alexa Fluor 488-labeled fibrinogen or isotype 
control antibodies without thrombin stimulation. All sample mixtures were then 
diluted with HEPEs buffer. The final volume each sample was brought to 100 µl. 
All samples were analyzed by Accuri C6 flow cytometer.  
The agonist thrombin is responsible for PLT activation and is measured as 
CD62P expression. To determine the surface expression of P-selectin (CD62P), 
PLTs were stimulated with 5 U/ml thrombin for 10 min at 37°C, then fixed with 
2% PFA for 30 min at RT, washed twice with HEPEs buffer, incubated with either 
FITC-conjugated anti-CD62P or FITC-conjugated mouse IgG isotype control for 
30 min at 4°C in the dark. A control group of PLTs underwent concurrent testing. 
The control PLTs were fixed without thrombin stimulation and stained. The final 
volume each sample was brought to 100 µl. All samples were analyzed by Accuri 
C6 flow cytometer. All antibody application concentrations followed manufacture 
instructions and guidelines. 
 
Morphologic Study of PLTs by TEM 
Culture medium containing PLTs released from generated MKs was gently 
collected and centrifuged at 150 × g for 20 min to remove nucleated cells. . 
Control samples of PLTs were obtained from human peripheral blood samples. 
Peripheral blood was collected from normal patient using standard phlebotomy 
techniques into a collection tube containing acid-citrated-dextrose (ACD) solution. 
The control blood sample was centrifuged at 150 × g for 20 min in order to obtain 
platelet-rich plasma (PRP). The supernatant and PRP were added with equal 
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volume of 0.5% glutaraldehyde in 0.1 M phosphate buffer, then centrifuged at 
1000 × g for 10 min to pellet PLTs. The pellets were then fixed with 500 µl 2% 
glutaraldehyde in 0.1 M phosphate buffer for 1 hr at 4°C and centrifuged again at 
1000 × g for 10 min. The samples were washed with 0.1 M phosphate buffer 3 
times (1 min each), fixed with 1% osmium tetroxide in 0.1 M phosphate buffer for 
2 hrs at 4°C and washed another 3 times (1 min each), then dehydrated with a 
graded ethanol series (50%, 75%, 95%, 100%) for 5 min each. Subsequently, the 
samples were treated with 100% propylene oxide 2 times (5 min each), and then 
treated with 1:2 ratio of spurr resin 812 and propylene oxide, followed by a 2:1 
ratio of spurr resin 812 and propylene oxide for 2 hrs. Finally, the samples were 
embedded in beam capsules with spurr resin 812 according to the manufacture’s 
instruction, baked at 60°C in a hot air oven overnight. Ultrathin sections (60-80 
nm) were prepared with MT7000, mounted on 300-mesh copper grids, stained 
with 2% uranyl acetate for 5 min, rinsed with double distilled water for 5 times, 
and allowed to dry. The specimens were then stained with lead citrate for 10 min 
(REYNOLDS, 1963), rinsed with double distilled water another 5 times and 
allowed to air dry. Finally, all specimens were examined with an EM 208 (Philips) 
transmission electron microscope at an accelerating voltage of 70 KV. 
 
Differentiation of Neurons from hESCs 
To differentiate hESCs into the neuron lineage, the 4th passage of hESCs were 
trypsinized as noted in the previous sections and cultured at a density of 1.6 × 
105 cells/well on fibronectin coated 6-well tissue culture plates or coverslips with 
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hESCs culture medium overnight. The culture medium was then removed and 
replaced with fresh NPBM medium supplemented with growth factors including 
10 ng/ml FGF, 10 ng/ml EGF, 10 ng/ml NGF,15 ng/ml BDNF, and 0.2 mM L-
glutamine and 1% antibiotic-antimycotic solution. Cells were cultured for 14 days. 
Control cells were cultured simultaneously in control culture medium (DMEM/F12 
with 10%FBS and 1% antibiotic-antimycotic solution) without cytokines for the 
same time period as the study cells.  
 
Immunofluorescence Staining of Generated Neurons 
The cells on coverslips were fixed with 2% PFA, washed with PBS,  
permeabilized with blocking buffer (goat serum or donkey serum with PBS/0.1% 
BSA and 0.3% triton X-100) for 30 min at RT, then incubated with rabbit anti-
nestin (1:200), mouse anti-β tubulin III (1:50), mouse anti-NeuN (1:50), rabbit 
anti-TH (1:1000), rabbit anti-GFAP (1:25) monoclonal antibodies overnight at 4°C 
in the dark, respectively. After 3 times washes, cells were incubated with 
corresponding secondary antibody Cy3-conjugated donkey anti-rabbit/mouse 
(1:250) or FITC-conjugated goat anti-mouse/rabbit (1:100) for 1 hr at RT, 
individually. Subsequently, cells were washed 3 times, incubated with 1 ml DAPI 
solution (final concentration: 0.4 µg/ml) for 5 min, mounted with fluorescence 
mounting solution and imaged under a confocal fluorescence microscope. To 
assess the differentiation rate, we counted the number of cells staining positive 
with a given antibody in 5 individual fields. Controls were imaged simultaneously.  
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Western Blot Analysis of Transcription Gene Expression in Differentiated 
Neuronal Cells 
Protein samples were obtained from undifferentiated hESCs and 
differentiated neuronal cells following treatment with lysis buffer. Briefly, culture 
medium was removed from both groups. Cells were washed with PBS 3 times (1 
min each). The cells were then scraped off the culture plates in 1 ml PBS, 
transferred to1.5 ml tubes, and centrifuged at 400 × g for 10 min. 50 µl ice-cold 
lysis buffer containing protease inhibitor was added to each cell pellet. Samples 
were centrifuged at 10,000 × g for 5 min. The supernatants were collected as 
protein. Protein concentrations were determined by the Bradford method using 
Bio Rad reagent (Bio Rad Laboratories, Hercules, CA). For gel loading, the final 
sample volume was corrected to 30 µg of total protein. To each of the samples, 
10 µl of loading buffer (40% glycerol, 50% Tris-HCL, 10% SDS, bromophenol 
blue, 0.4% β-mercaptoethanol) was added to samples and boiled for 5 min. Then 
samples were loaded onto 10% Tris-Glycine SDS-Page gel (Bio Rad 
Laboratories, Hercules, CA). The gel was electrophoresed at 100 V, 50 mA till 
the dye came close to the bottom of the gel. Proteins were transferred from the 
gel to a PVDF membrane overnight at 10 V, 50 mA. Then the PVDF membrane 
was blocked with 8 ml 5% non-fat milk in 1 × TBS-T buffer for 1 hr at RT. The 
primary monoclonal antibody rabbit anti-Oct4 (1:500) was probed and incubated 
overnight at 4°C. The membrane was washed with1× TBS-T buffer for 3 times (5 
min each), then probed with secondary antibody horse raddish peroxidase (HRP) 
conjugated goat anti rabbit (1:4000) for 1 hr at RT, washed with 1× TBS-T for 3 
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times more, and viewed via the chemiluminescence produced by the ECL 
substrate (Pierce) and captured by the Fuji LAS3000 imager (Japan). 
Subsequently, the membrane was washed with 1× TBS-T buffer another 3 times 
(5 min each), then stripped with stripping buffer for 15 min at RT, blocked with 
non-fat milk, incubated with primary monoclonal antibody mouse anti-Sox2 
(1:2000) overnight at 4°C, probed with secondary antibody HRP-conjugated 
donkey anti mouse (1:4000), washed and imaged as described above. β-actin 
was used to determine relative amounts of protein of interest (POI) as follows: 
normalized value: (POIdensity - Backgrounddensity) / ( Actindensity - Backgrounddensity). 
To do this, monoclonal antibody mouse anti β-actin (1:4000) and secondary 
antibody HRP-conjugated donkey anti mouse (1:40000) were used. Values were 
not excluded from the final data calculations unless one of the bands was 
missing. This method of simultaneous probing is well-established and has been 
described previously (Mouihate et al, 2002). 
 
Statistic Analysis 
Results were described as mean ± SEM from at least three independently 
conducted experiments, unless otherwise specified. The p value < 0.05 was 
considered to be statistically significant in the paired t-test. All experiments were 
repeated in triplicate and were all reproducible. 
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IV. RESULTS 
 
1. Morphology of hESCs 
Three days after plating, the cultured cells grew and formed small colonies (Fig 
4A). Then small colonies gradually formed large colonies (Fig 4B) and eventually 
formed a monolayer at approximately days 8-10 of culture (Fig 4C).  
A B C
	  	  
 
2. Characterization of hESCs 
After the 4th passage culture, the hESCs were identified by immunocytochemistry 
and flow cytometry. Using flow cytometry, the cultured cells highly positively 
stained with stromal cell specific markers CD90 (Fig 5A) and CD29 (Fig 5B), 
however, negatively stained with hematopoietic lineage markers CD45 (Fig 5C) 
and CD34 (Fig 5D). Summarized data (Fig 5E) demonstrated the percentages of 
Fig 4. Morphological study of hESCs under light microscope. Representative 
images of cultured cells: small colonies (A), large colonies (B), and confluence 
hESCs (C).  All magnification: 10 ×.
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phenotypic expression of CD90 (95.2 ± 2%, n=3), CD29 (96.4 ± 3%, n=3), CD45 
(1.2 ± 0.05%, n=3), and CD34 (1.15 ± 0.08%, n=3).  
Immunocytochemistry revealed the cultured cells exclusively positively stained 
CD90 (stromal marker) (Fig 5F), but negatively stained cytokeratin (epithelial 
marker) (Fig 5G).  
Fig 5. hESCs identification. Flow cytometric representative plots: A, CD90 
expression; B, CD29 expression; C, CD45 expression; D, CD34 expression 
(Black curve: antibodies; Red curve: isotypecontrol);  E, summarized data. 
Data was analyzed as mean ± SEM, n=3, respectively. Immunocytochemistry
data: F, CD90 staining; G, cytokeratin staining (Magnification: 20 x).      
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3. Characterization of hESCs-derived MKs by Immunocytochemistry 
Analysis  
After 7-10 days of differentiation, generated MKs could be visualized under the 
light microscope (Fig 6A). Upon immunofluorescence staining, the generated 
MKs positively expressed CD41a (Fig 6B1- 6B3) and CD42b (Fig 6C1- 6C3). 
Summarized data (Fig 6D) demonstrated the percentages of phenotypic 
expression of CD41a (38 ± 3% and 1 ± 0.5%, differentiation group vs. control 
group, P<0.01, n=3), and CD42b (27 ± 2.5% and 0.9 ± 0.4%, differentiation 
group vs. control group, P<0.01, n=3) in generated MKs. 
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Fig 6. Characterization of hESCs - derived MKs by immunocytochemistry.  A, 
generated MKs can be observed under light microscope after 7-10 days 
differentiation. B1, CD41a staining, C1,CD42b staining; B2-C2, PI staining; B3-
C3, merged; scale bar: 75 µm. D, summarized data shows MKs marker 
expression on differentiation and control cells. Data was analyzed as mean ±
SEM, *P < 0.01, n=3.
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4. Expression of Surface Protein Markers for hESCs-derived MKs by Flow 
Cytometric Analysis 
The flow cytometric data showed the positive expression of CD41a (Fig 7A), and 
CD42b (Fig 7B). Summarized data (Fig 7C) demonstrated the positive 
expression percentages of CD41a (39 ± 3% and 1 ± 0.09%, differentiation group 
vs. control group, P<0.01, n=3), and CD42b (28 ± 2% and 1.2 ± 0.06%, 
differentiation group vs. control group, P<0.01, n=3). This MK percentage values 
closely paralleled to those obtained from immunocytochemistry analysis. They 
were also consistent with the developmental scheme, because CD41a is 
expressed throughout megakaryocytopoiesis, while CD42b is expressed during 
the later stages of MK lineage developmental (Tomer, 2004). The number of MKs 
produced was approximately 5.5 x 104 MKs (CD41a +) versus 1.8 x 105 hESCs. 
Undifferentiated hESCs (control) were diploidy and the DNA ploidy was 2N (Fig 
7D). Generated MKs were polyploidy and the DNA ploidy ranged from 2N to16N 
(Fig 7E).   
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Fig 7. hESCs-derived MKs surface protein expression analysis by flow 
cytometry. Representative plot of CD41a expression (A), and CD42b expression 
(B) (Black curve: antibodies; Red curve: isotypecontrol); Summarized data (C) 
shows MK markers expression on differentiation and control cells. Data was 
analyzed as mean ± SEM, *P<0.01, n=3. Plot D shows DNA content of 
undifferentiated hESCs; Plot E shows the polyploidy of generated MKs.
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5. Expression of Surface Protein Markers for PLTs by Flow Cytometric 
Analysis 
Culture-derived PLTs were collected from the culture supernatant and incubated 
with fluorescence-conjugated antibody CD41a as described in the Materials and 
Methods section. The diameter of the PLTs is approximately 2-3 µm. A gate was 
fixed in the forward scatter and side scatter histogram by using of 2 µm and 4 µm 
calibration beads (Fig 8A). Collected PLTs were expressed with CD41a (90 ± 2%, 
n=3) within the fixed gate P1 (Fig 8B). The number of PLTs produced was 
approximately 3 x 105 PLTs versus 1.8 x 105 hESCs. PLT numbers were reported 
as a cumulative number up to the point of analysis. Summarized data (Fig 8C) 
showed the MK yield per input of hESC was approximately 0.31 ± 0.01(n=3), the 
MK yield per input of hESC was approximately 1.7 ± 0.25 (n=3). 	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6. Expression of Activation-dependent Antigens on Generated PLTs 
Normal functional PLTs, express certain cell surface antigens like CD62P and 
fibrinogen receptor (αIIbIIIa) when activated. P-selectin, presents on the surface 
of the α-granules of resting PLTs, and is mobilized to the plasma membrane after 
activation. The PLTs surface protein complex fibrinogen receptor αIIbIIIa changes 
confirmation after PLTs activation in its conversion to a functional fibrinogen 
receptor. 
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Fig 8. Generated PLTs surface protein expression analysis by flow cytometry. A, 
representative plot shows the population of PLTs (oval); 2 µm (circle) and 4 µm 
(square) calibration beads were used as internal size standards; B, CD41a 
expression in the cells gated on P1 (black curve, red curve: isotype control). C, 
summarized data of MK and PLT yield per input of hESC. Data was expressed 
as mean ± SEM, n=3.
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Our flow cytometric data showed that the generated PLTs expressed CD62P 
(Fig 9A) and exhibited fibrinogen binding capability (Fig 9C). Summarized data 
(Fig 9B) demonstrated the up-regulation of CD62P expression (26 ± 4 % and 2.5 
± 1%, thrombin stimulation group vs. control group, P<0.01, n=3) after thrombin 
stimulation. Summarized data (Fig 9D) showed the raise of fibrinogen binding 
(32 ± 3 % and 1 ± 0.4 %, thrombin stimulation group vs. control group, P<0.01, 
n=3) after thrombin stimulation. These results indicated that generated PLTs 
have the ability to become active PLTs.  
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Fig 9. Functional assay of the generated PLTs. Thrombin stimulation enhanced 
CD62P expression (A) and fibrinogen binding (C) in PLTs released from 
generated MKs (Black curve, thrombin stimulation; Red curve, isotypecontrol). 
Summarized data show the significant up-regulation of  CD62P expression (B) 
and fibrinogen binding (D) after thrombin activation. Data was analyzed as 
mean ± SEM, *P<0.01, n=3.
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7. Ultrastructural Similarities between Generated PLTs and Peripheral 
Blood Derived PLTs  
Generated PLTs were examined by TEM. The size and ultrastructural 
composition of the generated PLTs (Fig 10A and C) were similar to those of 
normal PLTs obtained from human peripheral blood (Fig 10B and D). A 
representative image of generated PLT displayed a discoid shape shown in Fig 
10C, similar in shape to the peripheral blood PLTs shown in Fig 10D. Generated 
PLTs also showed typical normal PLT features, such as storage granules and 
mitochondria. 
Fig 10. Electron micrographs of PLTs. Generated PLTs (A, C) show typical  
ultrastructural morphology and cellular organelles as PLTs obtained from 
peripheral blood (B,D). G: storage granules; M: mitochondria.
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8. Expression of Surface Protein Markers for hESCs-derived Neurons by 
Immunocytochemistry Analysis 
After 14 days differentiation, generated neurons exhibited typical neuronal 
morphology including pyramidal cell bodies and dendritic projections (Fig 11A) 
upon light microscopic examination. Immunocytochemical staining revealed that 
generated neurons were positively stained for neuron specific markers including 
nestin (Fig 11B1-B3), β-tublin III (Fig 11C1-C3), NeuN (Fig 11D1-D3), TH (Fig 
11E1-E3), and astrocyte marker GFAP (Fig 11F1-F3). Summarized data (Fig 
11G) showed the percentages of phenotypic expression of nestin (40 ± 4%, n=3), 
β-tublin III (37 ± 3%, n=3), NeuN (15 ± 2%, n=3), TH (14 ± 1%, n=3), and 
astrocyte marker GFAP (10 ± 3%, n=3). The control cells weakly expressed 
neuron and astrocyte markers (less than 1%).  
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9. Expression of Transcription Genes Oct4 and Sox2 in the Cells after 
Neuronal Differentiation 
Western blotting data showed the expressions of Oct4 (Fig 12A) and Sox2 (Fig 
12B) on undifferentiated hESCs (control) and differentiated neuronal cells. 
Fig 11.  Characterization of generated neurons. A, hESCs treated with neuron 
differentiation medium for 14 days (Magnification  20 x); B1, nestin staining; C1, 
β-tublin III staining; D1, NeuN staining; E1, TH staining; F1, GFAP staining;  B2-
F2, DAPI staining; B3-F3, merged; scale bar, 75 µM. G, summarized data. Data 
was analyzed as mean ± SEM, n=3.
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Summarized data (Fig 12C) demonstrated the significantly down-regulated 
expression of transcription genes (Oct4: 0.11 ± 0.01and 0.32 ± 0.01, and Sox2: 
0.25 ± 0.02 and 0.52 ± 0.03, differentiated group vs. control group, P<0.01, n=4) 
in generated neurons. 
Fig 12. Comparison of  the transcription genes expression in neuron 
differentiation and control cells. Representative bands show the decreased 
expression of Oct4 (A) and Sox2 (B) in neuronal differentiation cells as 
compared with control cells. Summarized data (C). Data was analyzed as mean 
± SEM, *p<0.01, n=4.
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V. DISCUSSION 
 
The major findings of this study are as follows. 1) MKs and functional PLTs can 
be generated in vitro from hESCs. The generated PLTs have similar 
ultrastructural morphology and functional features with normal PLTs from human 
peripheral blood. 2) Neuons can also be differentiated from hESCs in an in vitro 
culture system.  
Human endometrium is characterized by its self-renewal and cyclic regeneration 
as part of the normal physiologic course of menstrual cycle in reproductive age 
females. The upper functionalis layer is shed at menstruation and is thought to 
regenerate, to a thickness of 0.5 - 1 mm to 5 - 7 mm, from progenitor cells 
located in the remaining basalis layer (Padykula, 1991). Recent studies have 
provided evidence for the existence of stromal progenitor cells in endometrium 
(Chan et al, 2004;Dimitrov et al, 2008;Schwab et al, 2005;Wolff et al, 2011). 
Based on these reports, we cultured hESCs from human endometrial tissue in 
this study. The primary cultured cells were composed of a heterogeneous 
population of stromal cells, epithelial cells and erythrocytes. As Dimitrov et al 
reported that the frequency of the cells other than hESCs diminishes quickly 
through 2 - 3 passages in the culture system (Dimitrov et al, 2008), we used 
passages 4 - 6th of hESCs for the differentiation in our experiments. We found 
that the cultured hESCs of passages 4-6th exclusively expressed stromal cell 
marker CD90 with none cells expressing epithelial cell marker cytokeratin by 
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immunocytochemistry analysis. Further analysis by flow cytometry convincingly 
demonstrated that more than 95% hESCs (P4-P6) were positive for stromal cell 
markers (CD29 and CD90) and negative for hematopoietic cell markers (CD34 
and CD45). These data are in agreement with previous findings that showed 
similar phenotypic expression profiles for their respective hESCs (Chan et al, 
2004; Dimitrov et al, 2008; Schwab et al, 2005), demonstrating the stromal 
progenitor cells exist in the endometrial tissue. 
Recent studies have reported on hESCs as a source of multipotent cells that are 
capable of differentiating into multiple cell lineages including smooth muscle cells, 
adipocytes, chondrocytes, and osteoblasts (Gargett et al, 2009). Additionally, one 
recent publication described neuron differentiation potentiality from hESCs (Wolff 
et al, 2011). But there are no reports on generating MKs and PLTs from hESCs. 
The process of MK differentiation and subsequent PLT release by mature MKs 
are influenced by a variety of cytokines and growth factors. TPO is the primary 
cytokine to support the proliferation and maturation of MKs (Alexander et al, 1996; 
Gurney et al, 1994; Kaushansky et al, 1994; Kaushansky, 1995; Schipper et al, 
1998). It also plays an important role in the formation and function of PLTs in 
vitro (Choi et al, 1995; Choi et al, 1996; Kaushansky, 1998). Hence, TPO has 
been widely used in research and in a number of studies on MK and PLT 
differentiation (Chen et al, 2009; Fujimoto et al, 2003). Serum is an important 
supportive component in cell cultures, but it is also a potential source of bacterial, 
mycoplasmal, and viral contamination and could induce immune-response.  
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Herein, we firstly described a culture system in which MKs and PLTs can be 
differentiated from hESCs in serum-free medium supplemented with TPO. The 
hESCs-derived MKs and PLTs expressed typical MK and PLT specific plasma 
membrane glycoprotein markers (eg, CD41a, CD42b). Stimulation of generated 
PLTs through soluble agonist thrombin resulted in activation of the fibrinogen 
receptor (αIIbIIIa) and enhanced expression of surface antigen P-selectin 
(CD62P). Electron microscopy studies showed that our generated PLTs have 
similar morphological and ultrastructural features as PLTs obtained from human 
peripheral blood including a discoid shape, the presence of storage granules and 
other organelles like mitochondria. These data are consistent with previous 
studies about in vitro generated MKs and PLTs from other tissue of origin 
sources (Choi et al, 1995;Fujimoto et al, 2003;Matsubara et al, 2009;Ungerer et 
al, 2004).  
Matsubara and colleagues have generated approximately 2 × 106 MKs and 1.5 × 
105 PLTs from 107 adipocyte precursor cells (Matsubara et al, 2009). The 
Takayama group reported that about 2 - 5 ×105 MKs and 105 PLTs were 
produced from 105 human embryonic stem cells (Takayama et al, 2008). In the 
present study, we obtained approximately 5.5 x 104 MKs and 3 x 105 PLTs from 
1.8 x 105 hESCs. The differentiation efficiency of MKs to PLTs among various 
stem cell sources renders precise comparisons difficult. However, the number of 
PLTs released from our hESCs-derived MKs was below the theoretical range 
proposed in other study in which approximately 1000 to 5000 PLTs per MK has 
been reported to be released in vivo from mature MKs (Patel et al, 2005). 
	  
45	  
	  
Release of PLTs from mature MKs is influenced by multiple factors within the BM 
microenvironment (Larson & Watson, 2006;Patel et al, 2005). The low efficiency 
of PLT release from hESCs-derived MKs may be related to the absence of some 
in vivo  stimulus of thrombopoiesis, such as shear flow (Junt et al, 2007), in the in 
vitro culture system. Despite these findings, the present study is the first to report 
that MKs can be feasibly generated from hESCs and the generated MKs 
released PLTs conformed morphologically and functionally with PLTs obtained 
from human peripheral blood samples. The capacity to generate functional PLTs 
from hESCs in vitro provides a promising source for PLT in transfusion medicine. 
Menorrhagia is well recognized as a bleeding disorder in women with inherited 
bleeding disorders (James, 2005;Kadir et al, 1999). PFDs are inherited bleeding 
disorders frequently found among patients with bleeding diatheses. PFDs occur 
in 50% of women with unexplained menorrhagia and are prevalent in adolescent 
with menorrhagia as well (Chi et al, 2010; El-Hemaidi et al, 2007; Hossain et al, 
2010; Philipp et al, 2003). However, the management of menorrhagia is 
suboptimal in some patients with PFDs. Some patients are refractory to medical 
therapy and require repeated PLT transfusions. One possible consequence of 
this study is in vitro generating PLTs with normal function from hESCs provides a 
potential therapeutic approach to menorrhagia.  
 
In the present study we also reported that neurons can be generated from 
hESCs in a neuron differentiation medium with growth factors EGF, FGF, NGF 
and BDNF. Neurotrophic factors (EGF, FGF, NGF, and BDNF) are survival 
	  
46	  
	  
and/or differentiation factors for neuron progenitor cells. EGF plays an important 
role in the regulation of cell growth, proliferation and differentiation (Carpenter & 
Cohen, 1990). FGF has long been known as a key regulator of neuron stem cell 
proliferation and differentiation (Palmer et al, 1999). The importance of FGF in 
vivo for neurogenesis has been confirmed by the neural defects observed in 
FGF-deficient mice (Vaccarino et al, 1999). NGF is the first of a series of 
neurotrophins shown to mediate the survival of neurons (Freeman et al, 2004). 
BDNF is found to support the survival of existing neurons, and encourage the 
growth and differentiation of new neurons and synapses (Huang & Reichardt, 
2001). 
In this study, hESCs following neural differentiation revealed 
immunocytochemical characteristics of neural lineages. Generated neurons 
exhibited neuron morphology including pyramidal cell bodies and dendritic 
projections, and positively stained with neuron specific markers nestin (a 
filamentous protein expressed by neuronal precursor stem cells) (Lendahl et al, 
1990), β tubulin III (a marker expressed in immature neurons) (Lee et al, 1990), 
NeuN (a neuron-specific marker expressed in postmitotic cells) (Sarnat et al, 
1998), and astrocyte marker GFAP (an intermediate filament protein expressed 
by astrocytes in the central nervous system). These results are consistent with 
published data of BM stromal cells, which express both neuron and glial cell 
markers after neuron induction (Lu et al, 2006;Sanchez-Ramos et al, 2000). 
Interestingly, the catecholaminergic marker TH, which is the rate-limiting enzyme 
for dopamine synthesis, is also expressed.  
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Oct4, a member of the POU family of transcription factors, is characteristically 
expressed in embryonic cells and necessary for their pluripotency (Pesce & 
Scholer, 2000). Sox2 is one of the SoxB1family of transcription factors, which are 
also crucial for stem cell pluripoteny. In our study, we observed that Oct4 and 
Sox2 were expressed in the initial hESCs population, suggesting that these 
hESCs contain pluripotent progenitors. After neuronal differentiation, the 
expression levels of Oct4 and Sox2 were found to be significantly reduced. This 
finding is in agreement with previous study that reported Oct4 is expressed by 
some individual stromal cells in human endometrium (Matthai et al, 2006) and 
supports the neuronal differentiation scheme.  
Stroke remains a leading cause of death and disability worldwide. Neural tissue 
has limited potential for intrinsic repair following injury. Stem cell therapy is 
promising for neural regeneration and thus becomes one of the current trends. 
An increasing number of studies have shown that stem cell treatment of stroke 
acts to increase cell survival and angiogenesis, improve synapse formation, and 
reduce inflammatory responses (Bacigaluppi et al, 2009; Lindvall & Kokaia, 2004; 
Martino & Pluchino, 2006). The capacity to generate neurons from hESCs in vitro 
provides a promising source of transplantation therapy for stroke and 
neurodegenerative diseases. 
One shortcoming of the present study was that we relied only on the 
morphological changes and protein level of transcriptional genes expression to 
define the events during neuroectodermal conversion of hESCs. A previous 
	  
48	  
	  
study attempted to perform electrophysiological experiments on putative neurons 
derived from hESCs without showing the action potential (Wolff et al, 2011). In 
future studies, we will investigate the membrane action current of generated 
neurons using standard whole-cell patch-clamp technique and perform the in vivo 
transplantation study.  
We will also investigate the differentiation efficiency of PLTs generated from 
induced pluripotent stem (iPS) cells. iPSCs are a type of pluripotent stem cells 
that have been reprogrammed from fibroblast cells obtained from either fibroblast 
cells obtained from either human adult dermal cells, fetuses, or newborn foreskin 
with defined transcriptional factors (Oct4, Sox2, Klf, C-myc) (Takahashi et al, 
2007;Yu et al, 2007). PLTs are terminally differentiated, anucleate cells. PLTs 
are unable to retain the pluripotent or tumorigenic properties of iPSCs. A 
previous finding has already indicated that MKs and PLTs can be generated from 
hiPSCs, and produced PLTs showed normal function in vivo (Takayama et al, 
2010). Based on these studies, a feasible approach to overcome the relative low 
efficiency issue is to reprogram iPSCs from hESCs and then differentiate the 
iPSCs into MKs and PLTs. Such an approach to generating PLTs from hESCs 
could potentially lead to a constant and safe source of PLTs. 
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VI. CONCLUSION 
 
In conclusion, 1) our results reported on the feasibility of differentiating hESCs 
into MKs that subsequently release functional PLTs. This process is achieved 
using serum-free medium in the presence of TPO in an in vitro culture system.  
The generated PLTs have the potential to serve as an alternative source of PLT 
concentrates for future use in transfusion medicine to treat PLT-related bleeding 
disorders like menorrhagia. 
2) Our data demonstrated that hESCs can be differentiated into neurons 
accompany with reduced expression of multipotent transcription genes (Oct4 and 
Sox2). Correspondingly, these data indicate that hESCs could serve as an 
alternative source for producing neurons in an in vitro culture system. The 
generated neurons could be a potential source of cell-based therapy to treat 
stroke, and other neurodegenerative diseases. 
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